Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;141(2):295-305.
doi: 10.1007/s00432-014-1757-5. Epub 2014 Jul 3.

Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature

Omar Abdel-Rahman  1 , Mona Fouad
Affiliations

Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature

Omar Abdel-Rahman et al. J Cancer Res Clin Oncol. 2015 Feb.

Abstract

Background: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) consist of a large heterogeneous group of epithelial tumors with neuroendocrine differentiation that arises in gastrointestinal tract and pancreatic tissues. Advanced GEP-NENs are considered distinct disease entity with limited approved treatment options and poor prognosis. So, we will explore in this systematic review the value of using bevacizumab-based combination in this subset of NENs.

Methods: PubMed, Medline, the Cochrane Library, trip database and Google Scholar were searched using the terms "GEP-NENs" OR "Gastroenteropancreatic neuroendocrine tumors" AND "systemic anticancer therapy" AND "Bevacizumab" and selecting only the English literature. Outcomes of interest included progression-free survival and overall survival (PFS and OS), tumor response and toxicities.

Results: A total of 17 potentially relevant trials were identified, of which eight studies were excluded. Hence, nine trials involving 320 patients were included. Median PFS was reported in eight out of the nine studies ranging from 8.2 to 16.5 months. Median OS was reported in one study, and it was 33.3 months for the whole group. The disease control rate was reported in the seven studies, and it ranged from 80 to 96%. The overall response rate was reported in eight studies, and it ranged from 0 to 64%. Frequently reported grade 3/4 toxicities were gastrointestinal toxicities, mucocutaneous toxicities and hematologic toxicities (particularly leucopenia).

Conclusions: The current evidence from the available clinical trials suggests that bevacizumab in combination with some other anticancer agents (especially mTOR inhibitors and interferons) could be a more effective and tolerable treatment for advanced GEP-NENs in the future. However, such bevacizumab-based combination cannot be recommended outside the setting of clinical trials.

PubMed Disclaimer

Conflict of interest statement

We have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Flowchart of study selection procedure
See this image and copyright information in PMC

References

    1. Aaltonen L, Hamilton S (2000) World Health Organization. Oxford, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system. IARC Press; Oxford University Press Distributor, Lyon
    1. Abdel-Rahman O, Fouad M (2014) Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta-analysis. Expert Rev Anticancer Ther [Epub ahead of print] - PubMed
    1. Abdel-Rahman O, Abdelwahab M, Shaker M, AbdelWahab S, Elbassiony M, Ellithy M (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol (3):655. doi:10.1007/s12032-013-0655-z. Epub 2013 Jul 4 - PubMed
    1. Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E et al (2014) Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer 14(1):184. doi:10.1186/1471-2407-14-184 - PMC - PubMed
    1. Bosman F (2010), World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. (4th ed.)International Agency for Research on Cancer, Lyon

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources